Exploring the anti-cancer potential of dark tea

Amgen believes Blincyto, first granted accelerated approval in 2018, has been reinforced as standard of care. Credit: Shutterstock / Chalie Chulapornsiri. Based on a trial

Share this article The fast track designation is set to expedite the development and review of EDG-5506. Credit: Gorodenkoff / Shutterstock.com. The US Food and

Rep. An­na Es­hoo (D-CA) called out the FDA for hav­ing yet to pub­lish guid­ance for in­dus­try on draft­ing di­ver­si­ty ac­tion plans for clin­i­cal tri­als dur­ing